fibrin and Hermanski-Pudlak-Syndrome

fibrin has been researched along with Hermanski-Pudlak-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for fibrin and Hermanski-Pudlak-Syndrome

ArticleYear
Defective PDI release from platelets and endothelial cells impairs thrombus formation in Hermansky-Pudlak syndrome.
    Blood, 2015, Mar-05, Volume: 125, Issue:10

    Protein disulfide isomerase (PDI), secreted from platelets and endothelial cells after injury, is required for thrombus formation. The effect of platelet and endothelial cell granule contents on PDI-mediated thrombus formation was studied by intravital microscopy using a mouse model of Hermansky-Pudlak syndrome in which platelet dense granules are absent. Platelet deposition and fibrin generation were nearly absent, and extracellular PDI was significantly reduced in HPS6(-/-) mice after vascular injury. HPS6(-/-) platelets displayed impaired PDI secretion and impaired exocytosis of α granules, lysosomes, and T granules due to decreased sensitivity to thrombin, but these defects could be corrected by addition of subthreshold amounts of adenosine 5'-diphosphate (ADP). Human Hermansky-Pudlak syndrome platelets demonstrated similar characteristics. Infusion of wild-type platelets rescued thrombus formation in HPS6(-/-) mice. Human umbilical vein endothelial cells in which the HPS6 gene was silenced displayed impaired PDI secretion and exocytosis of Weibel-Palade bodies. Defective thrombus formation in Hermansky-Pudlak syndrome, associated with impaired exocytosis of residual granules in endothelial cells and platelets, the latter due to deficiency of ADP, is characterized by a defect in T granule secretion, a deficiency in extracellular PDI secretion, and impaired fibrin generation and platelet aggregation. Hermansky-Pudlak syndrome is an example of a hereditary disease whereby impaired PDI secretion contributes to a bleeding phenotype.

    Topics: Adenosine Diphosphate; Animals; Apyrase; Blood Platelets; Cell Degranulation; Disease Models, Animal; Endothelial Cells; Exocytosis; Female; Fibrin; Hermanski-Pudlak Syndrome; Human Umbilical Vein Endothelial Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Aggregation; Protein Disulfide-Isomerases; RNA, Small Interfering; Thrombin; Thrombosis; Vesicular Transport Proteins

2015
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.
    Cell, 2009, Dec-11, Volume: 139, Issue:6

    Platelets play a central role in thrombosis, hemostasis, and inflammation. We show that activated platelets release inorganic polyphosphate (polyP), a polymer of 60-100 phosphate residues that directly bound to and activated the plasma protease factor XII. PolyP-driven factor XII activation triggered release of the inflammatory mediator bradykinin by plasma kallikrein-mediated kininogen processing. PolyP increased vascular permeability and induced fluid extravasation in skin microvessels of mice. Mice deficient in factor XII or bradykinin receptors were resistant to polyP-induced leakage. PolyP initiated clotting of plasma via the contact pathway. Ablation of intrinsic coagulation pathway proteases factor XII and factor XI protected mice from polyP-triggered lethal pulmonary embolism. Targeting polyP with phosphatases interfered with procoagulant activity of activated platelets and blocked platelet-induced thrombosis in mice. Addition of polyP restored defective plasma clotting of Hermansky-Pudlak Syndrome patients, who lack platelet polyP. The data identify polyP as a new class of mediator having fundamental roles in platelet-driven proinflammatory and procoagulant disorders.

    Topics: Animals; Blood Platelets; Bradykinin; Factor XII; Fibrin; Hermanski-Pudlak Syndrome; Humans; Inflammation Mediators; Mice; Peptide Hydrolases; Plasma; Polyphosphates; Receptors, Bradykinin; Thrombosis

2009